Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Hypersensitivity Reaction

Free Subscription Articles published in J Am Acad Dermatol Retrieve available abstracts of 265 articles: HTML format

Single Articles

November 2024
1. BRODELL RT
   JAAD Game Changers: "Diet in dermatology: Part I. Atopic dermatitis, acne, and nonmelanoma skin cancer".
   J Am Acad Dermatol. 2024 Nov 28:S0190-9622(24)03276.
   PubMed    
   
   
   
2. CHOI UE, Deng J, Parthasarathy V, Liao V, et al
   Risk factors and temporal associations of progression of the atopic march in children with early-onset atopic dermatitis.
   J Am Acad Dermatol. 2024 Nov 28:S0190-9622(24)03273.
   PubMed     Abstract available
   
   
   
3. MASISON J, Beltrami EJ, Gronbeck C, Feng H, et al
   Differential patient travel burden to pediatric atopic dermatitis clinical trial sites.
   J Am Acad Dermatol. 2024 Nov 8:S0190-9622(24)03109.
   PubMed    
   
   
   October 2024
4. SINGAL A, Lipner HI, Neubauer Z, Lipner SR, et al
   Higher Sodium Excretion Is Not Associated With Increased Odds of Developing Atopic Dermatitis in a Large Retrospective Cohort Study.
   J Am Acad Dermatol. 2024 Oct 21:S0190-9622(24)03032.
   PubMed    
   
   
   
5. PALLER AS, de Bruin-Weller M, Marcoux D, Baselga E, et al
   Real-world treatment outcomes of systemic treatments for moderate-to-severe atopic dermatitis in children aged less than 12 years: 2-year results from PEDISTAD.
   J Am Acad Dermatol. 2024 Oct 8:S0190-9622(24)02919.
   PubMed     Abstract available
   
   
   
6. ELGHAZZAWY MB, Nassir S, Arora JS, Min MS, et al
   A retrospective cohort study investigating cutaneous vasculitis in the setting of COVID-19 notes higher rates of IgA vasculitis.
   J Am Acad Dermatol. 2024;91:757-759.
   PubMed    
   
   
   
7. OBIJIOFOR CE, Sikora M, Liu L, Stern MJ, et al
   Investigating corrected QT prolongation with hydroxychloroquine use among patients with cutaneous sarcoidosis: A multicenter retrospective study.
   J Am Acad Dermatol. 2024;91:740-742.
   PubMed    
   
   
   September 2024
8. NGUYEN TV, Marcus AF, Sinnott SJ, Coleman A, et al
   Commentary: Response to "Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: a retrospective cohort study".
   J Am Acad Dermatol. 2024 Sep 30:S0190-9622(24)02901.
   PubMed    
   
   
   
9. PALLER AS, Silverberg JI, Simpson EL, Cork MJ, et al
   The effect of dupilumab on caregiver- and patient-reported outcomes in young children with moderate-to-severe atopic dermatitis: results from a placebo-controlled, phase 3 study.
   J Am Acad Dermatol. 2024 Sep 28:S0190-9622(24)02896.
   PubMed     Abstract available
   
   
   
10. GUILLEMIN C, Bellon N, Jachiet M, Barbarot S, et al
    Dupilumab in atopic-dermatitis-like eczema associated with inborn errors of immunity: a nationwide study.
    J Am Acad Dermatol. 2024 Sep 27:S0190-9622(24)02885.
    PubMed    
    
    
    
11. NEUBAUER ZJK, Brunner PM, Geskin LJ, Guttman E, et al
    Decoupling the Association of Dupilumab with Cutaneous T-Cell Lymphoma Reply to "Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: A retrospective cohort study.".
    J Am Acad Dermatol. 2024 Sep 7:S0190-9622(24)02812.
    PubMed    
    
    
    
12. MATEI I, Bettuzzi T, Peiffer B, Ingen-Housz-Oro S, et al
    Evolution of the spectrum of drugs associated with acute generalized exanthematous pustulosis over time: A pharmacovigilance study.
    J Am Acad Dermatol. 2024;91:555-557.
    PubMed    
    
    
    
13. INGEN-HOUSZ-ORO S, Guichard E, Milpied B, Bensaid B, et al
    Topical versus oral corticosteroids in moderate drug reaction with eosinophilia and systemic symptoms: A multicenter randomized clinical trial.
    J Am Acad Dermatol. 2024;91:544-547.
    PubMed    
    
    
    August 2024
14. MA EZ, Bao A, Ahmadi M, Zhang J, et al
    Dupilumab is associated with reduced risk of acute upper respiratory infections in atopic dermatitis patients compared to non-targeted immunosuppressants: a multi-center cohort study.
    J Am Acad Dermatol. 2024 Aug 30:S0190-9622(24)02756.
    PubMed    
    
    
    
15. HASAN I, Zinn Z
    Response to Flynn et al. "Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: a retrospective cohort study.".
    J Am Acad Dermatol. 2024 Aug 27:S0190-9622(24)02727.
    PubMed    
    
    
    
16. CHO YT, Chu CY
    Comments on "dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T-cell lymphoma: a retrospective cohort study".
    J Am Acad Dermatol. 2024 Aug 24:S0190-9622(24)02739.
    PubMed    
    
    
    
17. FLYNN E, Leonard N, Svoboda R
    Response to Hasan et al.'s "Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: a retrospective cohort study.".
    J Am Acad Dermatol. 2024 Aug 23:S0190-9622(24)02726.
    PubMed    
    
    
    
18. CHAIYABUTR C, Dawe R, Lesar A, Ibbotson SH, et al
    Continuum of Light Sensitivity in Atopic Dermatitis: A Retrospective Analysis of 139 Cases in Scotland.
    J Am Acad Dermatol. 2024 Aug 22:S0190-9622(24)02710.
    PubMed     Abstract available
    
    
    
19. SEE TOW HX, Yeok-Loo Lim A, Ci-En Choi E
    Response to: Bocquel et al., "Impact of dupilumab on patch test results and allergic contact dermatitis: A prospective multicenter study".
    J Am Acad Dermatol. 2024 Aug 21:S0190-9622(24)02661.
    PubMed    
    
    
    
20. GEORGE SE, Yu J
    Tralokinumab as an Effective Alternative after Dupilumab Treatment Failure in Moderate-to-Severe Atopic Dermatitis: A Real-World Study.
    J Am Acad Dermatol. 2024 Aug 20:S0190-9622(24)02700.
    PubMed    
    
    
    
21. RIVA HR, Woodruff CM
    Allergens and consumer warnings in at-home acrylic manicure kits.
    J Am Acad Dermatol. 2024 Aug 13:S0190-9622(24)02655.
    PubMed    
    
    
    
22. KRIDIN K, Ludwig RJ
    Reply to: "Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: A retrospective cohort study".
    J Am Acad Dermatol. 2024 Aug 6:S0190-9622(24)02574.
    PubMed    
    
    
    
23. CHEN TL, Ma SH
    Comments on the risk of cutaneous T cell lymphoma among patients with atopic dermatitis receiving dupilumab.
    J Am Acad Dermatol. 2024 Aug 6:S0190-9622(24)02573.
    PubMed    
    
    
    
24. HEYMANN WR
    Dupilumab's duplicity.
    J Am Acad Dermatol. 2024;91:249-250.
    PubMed    
    
    
    
25. SAMARAKOON U, Wolfson AR, Zhou L, Bassir F, et al
    Understanding the patient experience of drug reaction with eosinophilia and systemic symptoms: A qualitative study.
    J Am Acad Dermatol. 2024;91:370-373.
    PubMed    
    
    
    
26. GEORGE SE, Yu J
    Patch testing outcomes in children at the Massachusetts General Hospital.
    J Am Acad Dermatol. 2024;91:354-356.
    PubMed    
    
    
    July 2024
27. ZIEBART RL, Haberecht H, Davis MD, Wetter DA, et al
    Vancomycin-Associated Drug induced Hypersensitivity Syndrome: A Retrospective Cohort Study.
    J Am Acad Dermatol. 2024 Jul 29:S0190-9622(24)02556.
    PubMed    
    
    
    
28. PEZZOLO E, Narcisi A, Gargiulo L, Di Lernia V, et al
    Successful response to upadacitinib in patients affected by prurigo nodularis and by atopic dermatitis with a predominant prurigo nodularis pattern: a multicenter case series study.
    J Am Acad Dermatol. 2024 Jul 22:S0190-9622(24)02538.
    PubMed    
    
    
    
29. ZHAO Y, Zhang L, Zhang J
    Efficacy and safety of stapokibart (CM310) in adults with moderate-to-severe atopic dermatitis: a multicenter, randomized, double-blind, placebo-controlled phase 3 trial.
    J Am Acad Dermatol. 2024 Jul 20:S0190-9622(24)02498.
    PubMed    
    
    
    
30. WU KJ, Wei KC
    Response to Hasan et al.'s "Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: a retrospective cohort study.".
    J Am Acad Dermatol. 2024 Jul 19:S0190-9622(24)02496.
    PubMed    
    
    
    
31. MEROLA JF, Chiou AS, During E, Foley P, et al
    Improved sleep parallels improvements in atopic dermatitis signs, symptoms, and quality of life in adult patients treated with dupilumab: 24-week results from the DUPISTAD study.
    J Am Acad Dermatol. 2024 Jul 13:S0190-9622(24)02483.
    PubMed    
    
    
    
32. SHIH PC, Wei JCC
    Response to Hasan et al.'s "Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: a retrospective cohort study.".
    J Am Acad Dermatol. 2024 Jul 11:S0190-9622(24)01041.
    PubMed    
    
    
    
33. HASAN I, Zinn Z
    Response to Shih et al. "Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: a retrospective cohort study.".
    J Am Acad Dermatol. 2024 Jul 10:S0190-9622(24)01046.
    PubMed    
    
    
    
34. MCKENZIE NC, Buras MR, Yiannias JA, Hall MR, et al
    Cost-effectiveness of patch testing allergens within the same group - a computational approach to optimize formaldehyde-related allergen selection.
    J Am Acad Dermatol. 2024 Jul 5:S0190-9622(24)01000.
    PubMed     Abstract available
    
    
    
35. BAO A, Su HJ, Wan J
    Comparative Safety Analysis of Anti-IL-4/IL-13 Inhibitors and JAK Inhibitors in Atopic Dermatitis.
    J Am Acad Dermatol. 2024 Jul 4:S0190-9622(24)01003.
    PubMed    
    
    
    
36. BRODELL RT
    JAAD Game Changer: Etanercept therapy for toxic epidermal necrolysis.
    J Am Acad Dermatol. 2024;91:191.
    PubMed    
    
    
    June 2024
37. GRANT-KELS JM
    JAAD Game Changers: "Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate".
    J Am Acad Dermatol. 2024 Jun 13:S0190-9622(24)00901.
    PubMed    
    
    
    
38. LIN TL, Fan YH, Fan KS, Juan CK, et al
    Reduced atopic march risk in pediatric atopic dermatitis patients prescribed dupilumab versus conventional immunomodulatory therapy: A population-based cohort study.
    J Am Acad Dermatol. 2024 Jun 13:S0190-9622(24)00788.
    PubMed     Abstract available
    
    
    
39. KEOW S, Abu-Hilal M
    Effectiveness of abrocitinib for the treatment of moderate-to-severe atopic dermatitis in patients switched from dupilumab and/or tralokinumab: A real-world retrospective study.
    J Am Acad Dermatol. 2024 Jun 8:S0190-9622(24)00891.
    PubMed    
    
    
    
40. GANTZ HY, Greenzaid JD, Feldman SR
    Atopic dermatitis may not confer clinically meaningful risk of inflammatory bowel disease or renal malignancy.
    J Am Acad Dermatol. 2024 Jun 4:S0190-9622(24)00841.
    PubMed    
    
    
    
41. YAMANAKA-TAKAICHI M, Watanabe M, Comfere NI, Sokumbi O, et al
    Differentiating generalized pustular psoriasis from acute generalized exanthematous pustulosis.
    J Am Acad Dermatol. 2024;90:1289-1291.
    PubMed    
    
    
    
42. CURTIS KK, Dillan MM, Sharma TR, Piktel J, et al
    COVID-19 infection increases the development of Stevens-Johnson syndrome and toxic epidermal necrolysis: A retrospective cohort analysis.
    J Am Acad Dermatol. 2024;90:1300-1302.
    PubMed    
    
    
    
43. WANG S, Laageide L, Phan V, Rosenbach M, et al
    Use of registry surveys in cutaneous sarcoidosis.
    J Am Acad Dermatol. 2024;90:1294-1296.
    PubMed    
    
    
    
44. SIMPSON EL, Silverberg JI, Worm M, Honari G, et al
    Dupilumab treatment improves signs, symptoms, quality of life, and work productivity in patients with atopic hand and foot dermatitis: Results from a phase 3, randomized, double-blind, placebo-controlled trial.
    J Am Acad Dermatol. 2024;90:1190-1199.
    PubMed     Abstract available
    
    
    
45. PATTERSON A
    JAAD Game Changer: Drug reaction with eosinophilia and systemic symptoms may occur within 2 weeks of drug exposure: A retrospective study.
    J Am Acad Dermatol. 2024;90:1318.
    PubMed    
    
    
    
46. ELSTON DM
    Letter from the Editor: Drug reaction with eosinophilia and systemic symptoms syndrome.
    J Am Acad Dermatol. 2024;90:1153-1154.
    PubMed    
    
    
    
47. BLUMENTHAL KG, Alvarez-Arango S, Kroshinsky D, Lo YC, et al
    Drug reaction eosinophilia and systemic symptoms: Clinical phenotypic patterns according to causative drug.
    J Am Acad Dermatol. 2024;90:1240-1242.
    PubMed    
    
    
    May 2024
48. RIGALI S, Cozzi C, Liszewski W
    Identification of the Pigments Used in Permanent Makeup and Their Ability to Elicit Allergic Contact Dermatitis.
    J Am Acad Dermatol. 2024 May 31:S0190-9622(24)00830.
    PubMed     Abstract available
    
    
    
49. WOHLTMANN WE
    JAAD Game Changers: "Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study".
    J Am Acad Dermatol. 2024 May 30:S0190-9622(24)00824.
    PubMed    
    
    
    
50. UBUKATA N, Hashizume H, Nakatani E, Sasaki H, et al
    Risk Factors and Drugs Associated with the Development of Drug-Induced Hypersensitivity Syndrome (DIHS)/Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): A Population-Based Cohort Study Using the Shizuoka Kokuho Database.
    J Am Acad Dermatol. 2024 May 23:S0190-9622(24)00816.
    PubMed    
    
    
    
51. SILVERBERG JI, Eichenfield LF, Hebert AA, Simpson EL, et al
    Tapinarof Cream 1% Once Daily: Significant Efficacy in the Treatment of Moderate to Severe Atopic Dermatitis in Adults and Children Down to 2 Years of Age in the Pivotal Phase 3 ADORING Trials.
    J Am Acad Dermatol. 2024 May 20:S0190-9622(24)00755.
    PubMed     Abstract available
    
    
    
52. ELSTON DM
    This month in JAAD: May 2024.
    J Am Acad Dermatol. 2024;90:930.
    PubMed    
    
    
    
53. SILVERBERG JI, Kirsner RS, Margolis DJ, Tharp M, et al
    Efficacy and safety of crisaborole ointment, 2%, in participants aged >/=45 years with stasis dermatitis: Results from a fully decentralized, randomized, proof-of-concept phase 2a study.
    J Am Acad Dermatol. 2024;90:945-952.
    PubMed     Abstract available
    
    
    
54. ZHANG L, Li X, Xu X, Le Y, et al
    Ixekizumab-induced urticaria is associated with the short duration of remission in psoriasis by activation of mast cells.
    J Am Acad Dermatol. 2024;90:970-976.
    PubMed     Abstract available
    
    
    
55. SAKUNCHOTPANIT G, Rohan TZ, Milosavljevic S, Patil MK, et al
    Procalcitonin: A potentially useful serum test in patients with dermatologic disease.
    J Am Acad Dermatol. 2024;90:1090-1091.
    PubMed    
    
    
    
56. WOHLTMANN WE
    JAAD Game Changer: Inhibition of tumor necrosis factor improves conventional steroid therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis in a cohort of patients.
    J Am Acad Dermatol. 2024;90:1114.
    PubMed    
    
    
    April 2024
57. ZHANG J, Boesjes CM, Loman L, Kamphuis E, et al
    Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: up to 5-year results from the daily practice BioDay Registry.
    J Am Acad Dermatol. 2024 Apr 21:S0190-9622(24)00641.
    PubMed     Abstract available
    
    
    
58. LEIBOWITZ R, Fischer A, Collins LF, Feldman RJ, et al
    HIV-related exclusion criteria in atopic dermatitis and prurigo nodularis clinical trials.
    J Am Acad Dermatol. 2024 Apr 12:S0190-9622(24)00633.
    PubMed    
    
    
    
59. HASAN I, Parsons L, Duran S, Zinn Z, et al
    Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: a retrospective cohort study.
    J Am Acad Dermatol. 2024 Apr 6:S0190-9622(24)00566.
    PubMed     Abstract available
    
    
    
60. POWERS CM, Piontkowski AJ, Orloff J, Pulsinelli J, et al
    Risk of lymphoma in patients with atopic dermatitis: A case-control study in the All of Us database.
    J Am Acad Dermatol. 2024 Apr 4:S0190-9622(24)00554.
    PubMed    
    
    
    March 2024
61. MANZAR D, Suntres E, Nair N, Patel Y, et al
    Elevation of Creatine Phosphokinase in Moderate-Severe Atopic Dermatitis is Associated with the use of JAK inhibitors but not Dupilumab: A Systematic Review and Meta-Analysis.
    J Am Acad Dermatol. 2024 Mar 28:S0190-9622(24)00538.
    PubMed    
    
    
    
62. HREN MG, Guenin S, Khattri S
    Successful use of dual biologic therapy targeting the Th2 and Th17 axes simultaneously to treat patients with atopic dermatitis and concomitant psoriasis, psoriatic arthritis, or inflammatory bowel disease.
    J Am Acad Dermatol. 2024 Mar 15:S0190-9622(24)00492.
    PubMed    
    
    
    
63. MARTINEZ-CABRIALES S, Coulombe J, Aaron M, Hussain SH, et al
    Preliminary summary and reclassification of cases from the Pediatric Research of Management in Stevens-Johnson syndrome and Epidermonecrolysis (PROMISE) study: A North American, multisite retrospective cohort.
    J Am Acad Dermatol. 2024;90:635-637.
    PubMed    
    
    
    
64. EBATA A, Ogawa-Momohara M, Fukaura R, Yamashita Y, et al
    Increased Janus kinase activation in cutaneous vasculitis.
    J Am Acad Dermatol. 2024;90:627-629.
    PubMed    
    
    
    February 2024
65. AFVARI S, Zippin JH
    Photodermatoses in patients with atopic dermatitis: A 10-year retrospective cohort study.
    J Am Acad Dermatol. 2024 Feb 17:S0190-9622(24)00132.
    PubMed    
    
    
    
66. MA EZ, Hooper SR, Seegan PL, Wan J, et al
    Association of atopic dermatitis with emotional and behavioral problems in childhood.
    J Am Acad Dermatol. 2024 Feb 4:S0190-9622(24)00242.
    PubMed    
    
    
    
67. WU CY, Wu CY, Li MC, Ho HJ, et al
    Association of Air Quality Index (AQI) with incidence of atopic dermatitis in Taiwan: A nationwide population-based cohort Study.
    J Am Acad Dermatol. 2024 Feb 2:S0190-9622(24)00207.
    PubMed     Abstract available
    
    
    
68. WATANABE Y, Watanabe T, Yamaguchi Y
    Anti-SS-A antibody is a potential predictor of severe Stevens-Johnson syndrome and toxic epidermal necrolysis: A retrospective cohort study.
    J Am Acad Dermatol. 2024;90:385-387.
    PubMed    
    
    
    January 2024
69. LEFEVRE MA, Nosbaum A, Mosnier A, Lenief V, et al
    Gene profiling in active dermatitis lesions strengthens the diagnosis of allergic contact dermatitis.
    J Am Acad Dermatol. 2024 Jan 10:S0190-9622(24)00059.
    PubMed     Abstract available
    
    
    
70. SHAH SA, Mitra N, Margolis DJ, Wan J, et al
    Heterogeneity in cutaneous infection prevalence and frequency by timing of childhood atopic dermatitis onset.
    J Am Acad Dermatol. 2024 Jan 9:S0190-9622(24)00055.
    PubMed    
    
    
    
71. AVALLONE G, Mastorino L, Tavoletti G, Macagno N, et al
    Clinical outcomes and management of JAK inhibitor-associated acne (JAKne) in patients with moderate-to-severe atopic dermatitis undergoing upadacitinib: A multicenter retrospective study.
    J Am Acad Dermatol. 2024 Jan 8:S0190-9622(24)00049.
    PubMed    
    
    
    
72. HEYMANN WR
    Atopic Dermatitis: The Perpetual Need for Science and Art.
    J Am Acad Dermatol. 2024 Jan 6:S0190-9622(24)00021.
    PubMed    
    
    
    December 2023
73. MEROLA JF, Ertmer B, Liang H, Yue X, et al
    Venous thromboembolism risk is lower in patients with atopic dermatitis than other immune-mediated inflammatory diseases: A retrospective, observational, comparative cohort study using US claims data.
    J Am Acad Dermatol. 2023 Dec 24:S0190-9622(23)03400.
    PubMed     Abstract available
    
    
    
74. KANTOR J
    This Month in JAAD International: February 2024: Atopic Dermatitis and diabetes.
    J Am Acad Dermatol. 2023 Dec 5:S0190-9622(23)03268.
    PubMed    
    
    
    November 2023
75. CRAVER AE, Chen GF, Cohen JM
    Association between Atopic Dermatitis and Hypertension and Hyperlipidemia: A Cross-Sectional Study in the All of Us Research Program.
    J Am Acad Dermatol. 2023 Nov 24:S0190-9622(23)03226.
    PubMed    
    
    
    
76. CHIESA FUXENCH ZC, Mitra N, Del Pozo D, Hoffstad O, et al
    Risk of Atopic Dermatitis and the atopic march paradigm in children of mothers with atopic illnesses: a birth cohort study from the United Kingdom.
    J Am Acad Dermatol. 2023 Nov 18:S0190-9622(23)03213.
    PubMed     Abstract available
    
    
    
77. DAVIS DMR, Drucker AM, Alikhan A, Bercovitch L, et al
    Executive summary: Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies.
    J Am Acad Dermatol. 2023 Nov 3:S0190-9622(23)02879.
    PubMed     Abstract available
    
    
    
78. DAVIS DMR, Drucker AM, Alikhan A, Bercovitch L, et al
    Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies.
    J Am Acad Dermatol. 2023 Nov 3:S0190-9622(23)02878.
    PubMed     Abstract available
    
    
    
79. FISHBEIN AB, Mukherji J, Demczuk M, Buranosky B, et al
    Biomarkers of Response to Topical Crisaborole in Mild/Moderate Pediatric Atopic Dermatitis Patients From Minimally Invasive Tape Strip Transcriptome.
    J Am Acad Dermatol. 2023 Nov 2:S0190-9622(23)03110.
    PubMed    
    
    
    October 2023
80. RONNSTAD ATM, Thomsen SF, Thyssen JP, Egeberg A, et al
    The burden of head-and-neck dermatitis in adults with atopic dermatitis and its association with asthma, rhinitis, and disease severity.
    J Am Acad Dermatol. 2023 Oct 28:S0190-9622(23)03046.
    PubMed    
    
    
    
81. REEDER MJ, Zhang D, Aravamuthan SR, Warshaw EM, et al
    More than Just MI: Retrospective Analysis of Patients with Isothiazolinone Allergy in North America, 2017-2020.
    J Am Acad Dermatol. 2023 Oct 23:S0190-9622(23)03035.
    PubMed     Abstract available
    
    
    
82. BOCQUEL S, Soria A, Raison-Peyron N, Badaoui A, et al
    Impact of dupilumab on patch-test results and allergic contact dermatitis: A prospective multicenter study.
    J Am Acad Dermatol. 2023 Oct 21:S0190-9622(23)03032.
    PubMed     Abstract available
    
    
    
83. DIAZ MJ, Haq Z, Abdi P, Tran JT, et al
    Association between alopecia areata and atopic dermatitis: a nested case-control study of the All of Us database.
    J Am Acad Dermatol. 2023 Oct 21:S0190-9622(23)03034.
    PubMed    
    
    
    
84. VEVERKA KA, Thng STG, Silverberg JI, Armstrong AW, et al
    Safety and efficacy of eblasakimab, an IL-13Ralpha1 monoclonal antibody, in adults with moderate-to-severe atopic dermatitis: a phase 1b, multiple-ascending dose study.
    J Am Acad Dermatol. 2023 Oct 20:S0190-9622(23)03029.
    PubMed     Abstract available
    
    
    
85. SCHMARTZ S, Welfringer-Morin A, Le Bourgeois M, Delacourt C, et al
    Respiratory complications in pediatric epidermal necrolysis: A retrospective study of 22 cases.
    J Am Acad Dermatol. 2023;89:857-859.
    PubMed    
    
    
    
86. REDDY S, Yi L, Shields B, Platts-Mills T, et al
    Alpha-gal syndrome: A review for the dermatologist.
    J Am Acad Dermatol. 2023;89:750-757.
    PubMed     Abstract available
    
    
    September 2023
87. PALLER AS, Siegfried E, Marron SE, Clark M, et al
    Development and validation of a caregiver-reported Numeric Rating Scale for measuring worst scratch/itch in patients aged 6 months to younger than 6 years with atopic dermatitis.
    J Am Acad Dermatol. 2023 Sep 29:S0190-9622(23)02880.
    PubMed    
    
    
    
88. CHEN YW, Chen HH, Huang WN, Hsu CY, et al
    Dupilumab alleviates pruritus regardless of skin improvement in adults with atopic dermatitis: a cohort study.
    J Am Acad Dermatol. 2023 Sep 24:S0190-9622(23)02858.
    PubMed    
    
    
    
89. BRODELL RT
    JAAD Game Changers: Dupilumab and the risk of conjunctivitis and serious infection in patients with atopic dermatitis: A propensity score-matched cohort study.
    J Am Acad Dermatol. 2023 Sep 22:S0190-9622(23)02851.
    PubMed    
    
    
    
90. WOHLTMANN W
    JAAD Game Changers: Prevalence of type 2 inflammatory diseases in pediatric patients with atopic dermatitis: Real-world evidence.
    J Am Acad Dermatol. 2023 Sep 15:S0190-9622(23)02731.
    PubMed    
    
    
    
91. OTT H, Abraham S, Kind B, Haufe E, et al
    Comment on: "Interim results from the PEDISTAD Real-World Registry by Paller et al. " - First results from the German TREATkids registry for children and adolescents with moderate to severe atopic dermatitis (AD).
    J Am Acad Dermatol. 2023 Sep 15:S0190-9622(23)02780.
    PubMed    
    
    
    
92. ISAQ NA, Link J
    Response to Papp et al.'s "Long-Term Safety and Disease Control with Ruxolitinib Cream in Atopic Dermatitis: Results From Two Phase 3 Studies".
    J Am Acad Dermatol. 2023 Sep 12:S0190-9622(23)02695.
    PubMed    
    
    
    
93. XU L, Sockler PG, Park G, Grossberg AL, et al
    Characterization of patient portal messaging use and content among a pediatric atopic dermatitis population: a cross-sectional study.
    J Am Acad Dermatol. 2023 Sep 11:S0190-9622(23)02687.
    PubMed    
    
    
    
94. BRODELL RT
    JAAD Game Changers: Relative efficacy of systemic treatments for atopic dermatitis.
    J Am Acad Dermatol. 2023 Sep 7:S0190-9622(23)02675.
    PubMed    
    
    
    
95. GRANT-KELS JM
    JAAD Game Changers: Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort.
    J Am Acad Dermatol. 2023 Sep 7:S0190-9622(23)02672.
    PubMed    
    
    
    
96. SORENSEN R
    JAAD Game Changers: Assessment of major comorbidities in adults with atopic dermatitis using the Charlson comorbidity index.
    J Am Acad Dermatol. 2023 Sep 2:S0190-9622(23)02656.
    PubMed    
    
    
    
97. WALLS AC, Faletsky A, Chu B, Micheletti RG, et al
    Epidemiology and diagnostic classification of adults presenting with an initial episode of leukocytoclastic vasculitis: A multicenter review of 440 patients.
    J Am Acad Dermatol. 2023;89:582-584.
    PubMed    
    
    
    
98. FILLEY AR, Woodruff CM
    The Modernization of Cosmetics Regulation Act of 2022: What dermatologists need to know.
    J Am Acad Dermatol. 2023;89:629-631.
    PubMed    
    
    
    August 2023
99. GEORGAKOPOULOS JR, Sheka D, Rankin B, Maliyar K, et al
    Real-world effectiveness and safety of upadacitinib for the treatment of atopic dermatitis in adult patients switched from dupilumab: a multicenter retrospective study.
    J Am Acad Dermatol. 2023 Aug 28:S0190-9622(23)02645.
    PubMed    
    
    
    
100. SORENSEN R
     Autoimmune diseases in adults with atopic dermatitis.
     J Am Acad Dermatol. 2023 Aug 26:S0190-9622(23)02632.
     PubMed    
     
     
     
101. JACKSON JM, Althoff A, Rasouliyan L, Long S, et al
     Cardiovascular comorbidities in atopic dermatitis: potential implications for use of JAK inhibitors.
     J Am Acad Dermatol. 2023 Aug 19:S0190-9622(23)02563.
     PubMed    
     
     
     
102. SCHNEEWEISS MC, Richard Wyss, Schneeweiss S, Anand P, et al
     Joint pain in patients with atopic dermatitis receiving treatment with dupilumab: a US nation-wide cohort study.
     J Am Acad Dermatol. 2023 Aug 19:S0190-9622(23)02518.
     PubMed    
     
     
     
103. FRIEDMAN A
     Cause-specific mortality in adults with atopic dermatitis.
     J Am Acad Dermatol. 2023 Aug 17:S0190-9622(23)02505.
     PubMed    
     
     
     
104. PETTY AJ, Emge DA, Blanchard SK, Selim MA, et al
     Pilot, open-label, single-arm clinical trial evaluating the efficacy of topical crisaborole for steroid refractory morphea.
     J Am Acad Dermatol. 2023;89:390-392.
     PubMed    
     
     
     
105. MCSWEENEY SM, Christou EAA, Maurer M, Grattan CE, et al
     Physical urticaria: Clinical features, pathogenesis, diagnostic work-up, and management.
     J Am Acad Dermatol. 2023;89:324-337.
     PubMed     Abstract available
     
     
     
106. SOOD S, Heung M, Georgakopoulos JR, Mufti A, et al
     Use of Janus kinase inhibitors for granulomatous dermatoses: A systematic review.
     J Am Acad Dermatol. 2023;89:357-359.
     PubMed    
     
     
     
107. RUTHERFORD A, Erickson S, Keimig E, Wickless HW, et al
     Fibrosing vasculitides: A heuristic for investigation.
     J Am Acad Dermatol. 2023;89:e71-e74.
     PubMed    
     
     
     July 2023
108. JOHNSON H, Aquino MR, Snyder A, Collis RW, et al
     Prevalence of allergic contact dermatitis in children with and without atopic dermatitis: A multicenter retrospective case-control study.
     J Am Acad Dermatol. 2023 Jul 29:S0190-9622(23)01270.
     PubMed     Abstract available
     
     
     
109. LEE SS, Kaushik A, Natsis N, Kusari A, et al
     A multimodal initiative improves general pediatric provider management of atopic dermatitis in children: A prospective interventional study.
     J Am Acad Dermatol. 2023 Jul 28:S0190-9622(23)00711.
     PubMed    
     
     
     
110. WEI BM, Fox LP, Kaffenberger BH, Korman AM, et al
     Drug-induced Hypersensitivity Syndrome / Drug Reaction with Eosinophilia and Systemic Symptoms. Part I. Epidemiology, Pathogenesis, Clinicopathological Features, and Prognosis.
     J Am Acad Dermatol. 2023 Jul 27:S0190-9622(23)02402.
     PubMed     Abstract available
     
     
     
111. WEI BM, Fox LP, Kaffenberger BH, Korman AM, et al
     Drug-induced Hypersensitivity Syndrome / Drug Reaction with Eosinophilia and Systemic Symptoms. Part II. Diagnosis and Management.
     J Am Acad Dermatol. 2023 Jul 27:S0190-9622(23)02403.
     PubMed     Abstract available
     
     
     
112. JOSHI TP, Bancroft A, DeLeon D, Garcia D, et al
     Association of Atopic Dermatitis with Substance Use Disorders: A Case-Control Study in the All of Us Research Program.
     J Am Acad Dermatol. 2023 Jul 14:S0190-9622(23)01361.
     PubMed    
     
     
     
113. GONG T, Zhang P, Ruan SF, Xiao Z, et al
     APOA4 as a novel predictor of prognosis in Stevens-Johnson syndrome/toxic epidermal necrolysis: A proteomics analysis from two prospective cohorts.
     J Am Acad Dermatol. 2023;89:45-52.
     PubMed     Abstract available
     
     
     
114. MCSWEENEY SM, Kloczko E, Chadha M, Sarkany R, et al
     Systematic review of the clinical characteristics and natural history of solar urticaria.
     J Am Acad Dermatol. 2023;89:138-140.
     PubMed    
     
     
     June 2023
115. SMITH B, Engel P, Javadi SS, Han G, et al
     Reply to "Association of Atopic Dermatitis with Graves' Disease and Hashimoto's Thyroiditis: A Case-Control Study in the All of Us Research Program".
     J Am Acad Dermatol. 2023 Jun 12:S0190-9622(23)01103.
     PubMed    
     
     
     
116. JOSHI TP, Bancroft A, Garcia D, Kahla JA, et al
     Association of Atopic Dermatitis with Graves' Disease and Hashimoto's Thyroiditis: A Case-Control Study in the All of Us Research Program.
     J Am Acad Dermatol. 2023 Jun 12:S0190-9622(23)01104.
     PubMed    
     
     
     
117. TONG Z, Zhang Y, Zhou K, Zou Y, et al
     An observational study of abrocitinib in adults with moderate-to-severe atopic dermatitis after switching from dupilumab.
     J Am Acad Dermatol. 2023 Jun 10:S0190-9622(23)01083.
     PubMed    
     
     
     
118. SHIELDS A, Yoon J, Barbieri JS
     Content Analysis of Health-Related Quality-of-Life Patient Reported Outcome Measures Used in Patients with Atopic Dermatitis.
     J Am Acad Dermatol. 2023 Jun 7:S0190-9622(23)01013.
     PubMed    
     
     
     
119. JOSHI I, Maczuga S, Flamm A
     Examining Occupational Characteristics of Patients with Allergic Contact Dermatitis: A Retrospective Claims- Based Analysis.
     J Am Acad Dermatol. 2023 Jun 1:S0190-9622(23)01000.
     PubMed    
     
     
     
120. BOWIE AC, Tadrous M, Thiruchelvam D, Ivers NM, et al
     A comparison of family physician and dermatologist topical corticosteroid prescriptions: A population-based cross-sectional study.
     J Am Acad Dermatol. 2023;88:1291-1299.
     PubMed     Abstract available
     
     
     
121. GINZBURG A, Agrawal S
     Microfoam plaster application at forehead to prevent postoperative eyelid edema in patients after hair transplantation.
     J Am Acad Dermatol. 2023;88:e299-e300.
     PubMed    
     
     
     May 2023
122. SCARBERRY KB, Mahlberg SJ, Nedorost S
     Trends in Positive Patch Tests to Formaldehyde-Containing Allergens Found in Personal Care Products.
     J Am Acad Dermatol. 2023 May 29:S0190-9622(23)00989.
     PubMed    
     
     
     
123. KO MJ, Tsai WC, Tsai PH, Hsu LY, et al
     Ultraviolet B Phototherapy Does Not Increase the Risk of Skin Cancer Among Patients with Atopic Dermatitis: A Population-Based Retrospective Cohort Study.
     J Am Acad Dermatol. 2023 May 24:S0190-9622(23)00977.
     PubMed     Abstract available
     
     
     
124. BLAUVELT A, Ladizinski B, Prajapati VH, Laquer V, et al
     Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: results from an open-label extension of the phase 3, randomized, controlled trial (Heads Up).
     J Am Acad Dermatol. 2023 May 23:S0190-9622(23)00966.
     PubMed     Abstract available
     
     
     
125. SMITH B, Engel P, Javadi SS, Han G, et al
     Association between atopic dermatitis and cardiovascular disease in a nationally representative United States population.
     J Am Acad Dermatol. 2023 May 22:S0190-9622(23)00967.
     PubMed    
     
     
     
126. O'HAGAN R, Caldas SA, Correa da Rosa JM, Guttman-Yassky E, et al
     The impact of atopic dermatitis on alopecia areata: A two-sample Mendelian randomization study.
     J Am Acad Dermatol. 2023 May 17:S0190-9622(23)00907.
     PubMed    
     
     
     
127. CHIRICOZZI A, Balato A, Fabbrocini G, Di Nardo L, et al
     Beneficial effects of upadacitinib on alopecia areata associated with atopic dermatitis: a multicenter retrospective study.
     J Am Acad Dermatol. 2023 May 9:S0190-9622(23)00765.
     PubMed    
     
     
     
128. LABIB A, Ju T, Yosipovitch G
     Emerging Treatments for Itch in Atopic Dermatitis: A Review.
     J Am Acad Dermatol. 2023 May 6:S0190-9622(23)00761.
     PubMed     Abstract available
     
     
     
129. PEZZOLO E, Gambardella A, Guanti M, Bianchelli T, et al
     Tralokinumab shows clinical improvement in patients with prurigo nodularis-like phenotype atopic dermatitis: a multicenter, prospective, open-label case series study.
     J Am Acad Dermatol. 2023 May 5:S0190-9622(23)00760.
     PubMed    
     
     
     
130. SILVERBERG JI, Simpson B, Abuabara K, Guttman-Yassky E, et al
     Prevalence and Burden of Atopic Dermatitis Involving the Head, Neck, Face, and Hand: A Cross Sectional Study from the TARGET-DERM AD Cohort.
     J Am Acad Dermatol. 2023 May 5:S0190-9622(23)00756.
     PubMed     Abstract available
     
     
     
131. SMITH JH, Silverberg JI
     Correlation of clinician-reported outcomes with patient-reported outcomes by race and ethnicity in patients with atopic dermatitis.
     J Am Acad Dermatol. 2023 May 4:S0190-9622(23)00754.
     PubMed    
     
     
     
132. HEYMANN WR
     Searching for a T-cell glitch in Gleich syndrome.
     J Am Acad Dermatol. 2023;88:1006-1007.
     PubMed    
     
     
     
133. SINGH K, Valido K, Swallow M, Okifo KO, et al
     Baseline skin cytokine profiles determined by RNA in situ hybridization correlate with response to dupilumab in patients with eczematous dermatitis.
     J Am Acad Dermatol. 2023;88:1094-1100.
     PubMed     Abstract available
     
     
     
134. CHEN JY, Yiannias JA, Davis MDP, Yang YW, et al
     Evaluating the utility of screening corticosteroids found in standard/baseline patch testing series.
     J Am Acad Dermatol. 2023;88:1173-1175.
     PubMed    
     
     
     
135. GALLARDO MA, Mallela T, Gilkey T, Himed S, et al
     Demographic and laboratory differences seen between acute generalized exanthematous pustulosis and drug reaction with eosinophilia and systemic symptoms: A cross-sectional analysis.
     J Am Acad Dermatol. 2023;88:1142-1145.
     PubMed    
     
     
     
136. MILANI-NEJAD N, Trinidad J, Kaffenberger BH
     Acute kidney injury in vancomycin-induced drug reaction with eosinophilia and systemic symptoms: A case-control study.
     J Am Acad Dermatol. 2023;88:1121-1123.
     PubMed    
     
     
     
137. MORGADO-CARRASCO D, Giacaman-Von der Weth M, Fusta-Novell X, Podlipnik S, et al
     Clinical response and long-term follow-up of 20 patients with refractory solar urticaria under treatment with omalizumab.
     J Am Acad Dermatol. 2023;88:1110-1111.
     PubMed    
     
     
     
138. NEILL BC, Dallo C, Rajpara A, Liu D, et al
     Use of the back of the hands to apply ointment.
     J Am Acad Dermatol. 2023;88:e187.
     PubMed    
     
     
     
139. ABISROR N, Mekinian A, Dechartres A, Groh M, et al
     Abnormal T-cell phenotype in episodic angioedema with hypereosinophilia (Gleich syndrome): Frequency, clinical implication, and prognosis.
     J Am Acad Dermatol. 2023;88:e243-e250.
     PubMed     Abstract available
     
     
     April 2023
140. STEFANKO NS, Quan VL, Chovatiya R
     Efficacy, Safety, and Treatment Patterns of Ruxolitinib 1.5% Cream in Adult Atopic Dermatitis: A Single Center Retrospective Study.
     J Am Acad Dermatol. 2023 Apr 22:S0190-9622(23)00727.
     PubMed    
     
     
     
141. YEUNG J, Gooderham MJ, Hong HC, Lynde C, et al
     Treat-to-target in the management of moderate-to-severe atopic dermatitis in adults: A Canadian perspective.
     J Am Acad Dermatol. 2023 Apr 19:S0190-9622(23)00520.
     PubMed    
     
     
     
142. KIM M, Del Duca E, Cheng J, Carroll B, et al
     Crisaborole reverses dysregulation of the mild to moderate atopic dermatitis proteome towards nonlesional and normal skin.
     J Am Acad Dermatol. 2023 Apr 11:S0190-9622(23)00542.
     PubMed     Abstract available
     
     
     
143. YOUNG K, Collis RW, Sheinbein D, Shope C, et al
     Retrospective review of pediatric patch testing results in skin of color.
     J Am Acad Dermatol. 2023;88:953-954.
     PubMed    
     
     
     
144. HUNG YT, Chen YW, Huang Y, Lin YJ, et al
     Acute graft-versus-host disease presenting as Stevens-Johnson syndrome and toxic epidermal necrolysis: A retrospective cohort study.
     J Am Acad Dermatol. 2023;88:792-801.
     PubMed     Abstract available
     
     
     March 2023
145. KANTOR J
     This Month in JAAD International: May 2023: Air pollution and atopic dermatitis.
     J Am Acad Dermatol. 2023 Mar 14:S0190-9622(23)00372.
     PubMed    
     
     
     
146. SCHODER K, Zhu Y, Schneeweiss S, Merola J, et al
     Use of systemic immunomodulating medications in pregnant women with atopic dermatitis: a nationwide US study.
     J Am Acad Dermatol. 2023 Mar 9:S0190-9622(23)00358.
     PubMed    
     
     
     
147. WALLACE EB, Khosravi H, Joyce CJ, Vleugels FR, et al
     Examining the epidemiology of coincident psoriasis and sarcoidosis: An observational cross-sectional study.
     J Am Acad Dermatol. 2023;88:661-663.
     PubMed    
     
     
     
148. NEILL BC, Willis CD, Neill JA, Hanson C, et al
     Treating isotretinoin-associated cheilitis with hydrocortisone-containing lip balm.
     J Am Acad Dermatol. 2023;88:e113.
     PubMed    
     
     
     February 2023
149. SMITH B, Engel P, Collier MR, Devjani S, et al
     Association between electronic-cigarette use and atopic dermatitis among United States adults.
     J Am Acad Dermatol. 2023 Feb 25:S0190-9622(23)00280.
     PubMed    
     
     
     
150. SHI VY, Chamberlain W, Siegfried E, Kraff-Cooper C, et al
     Practical management of ocular surface disease in patients with atopic dermatitis, with a focus on conjunctivitis: A review.
     J Am Acad Dermatol. 2023 Feb 15:S0190-9622(23)00196.
     PubMed     Abstract available
     
     
     
151. QIAN MF, Li S, Honari G, Sarin KY, et al
     Prevalence of allergic contact dermatitis following patch testing in patients with atopic dermatitis: a retrospective United States claims-based study.
     J Am Acad Dermatol. 2023 Feb 10:S0190-9622(23)00178.
     PubMed    
     
     
     
152. DEL DUCA E, Renert-Yuval Y, Pavel AB, Mikhaylov D, et al
     Proteomic characterization of atopic dermatitis blood from infancy to adulthood.
     J Am Acad Dermatol. 2023 Feb 9:S0190-9622(23)00172.
     PubMed     Abstract available
     
     
     
153. BAILEY K, Adamson AS
     Health care disparities and dermatology: A duty to delve deeper.
     J Am Acad Dermatol. 2023;88:e107-e108.
     PubMed    
     
     
     
154. FISHBEIN AB, Lor J, Penedo FJ, Forrest CB, et al
     Patient-reported outcomes for measuring sleep disturbance in pediatric atopic dermatitis: Cross-sectional study of the Patient Reported Outcomes Measurement Information System pediatric sleep measures and actigraphy.
     J Am Acad Dermatol. 2023;88:348-356.
     PubMed     Abstract available
     
     
     
155. SINGH P, Silverberg JI
     Outpatient utilization patterns for atopic dermatitis in the United States.
     J Am Acad Dermatol. 2023;88:357-363.
     PubMed     Abstract available
     
     
     
156. DUAN GY, Silverberg JI
     Sleep impairment in patients with chronic inflammatory skin diseases: A review of mechanisms and management.
     J Am Acad Dermatol. 2023;88:421-427.
     PubMed     Abstract available
     
     
     January 2023
157. YILDIRIM AM, Pradhan T, Zinn ZA
     Dupilumab treatment for atopic dermatitis is associated with decreased utilization of psychostimulants for attention deficit hyperactivity disorder: a retrospective cohort study.
     J Am Acad Dermatol. 2023 Jan 31:S0190-9622(23)00159.
     PubMed    
     
     
     
158. YOUNG K, Collis RW, Sheinbein D, Shope C, et al
     Pediatric Allergic Contact Dermatitis Registry Patch Testing Results from 2016-2022: A Retrospective Study of Age-Related Differences.
     J Am Acad Dermatol. 2023 Jan 19:S0190-9622(23)00086.
     PubMed    
     
     
     
159. SIDBURY R, Alikhan A, Bercovitch L, Cohen DE, et al
     Guidelines of care for the management of atopic dermatitis in adults with topical therapies.
     J Am Acad Dermatol. 2023 Jan 11:S0190-9622(23)00004.
     PubMed     Abstract available
     
     
     
160. SIDBURY R, Alikhan A, Bercovitch L, Cohen DE, et al
     Executive Summary: American Academy of Dermatology Guidelines of care for the management of atopic dermatitis in adults with topical therapies.
     J Am Acad Dermatol. 2023 Jan 6:S0190-9622(23)00056.
     PubMed    
     
     
     
161. KESKITALO PL, Jokelainen J, Tasanen K, Sinikumpu SP, et al
     Juvenile idiopathic arthritis in children and adolescents with atopic dermatitis: A Finnish nationwide registry study.
     J Am Acad Dermatol. 2023 Jan 3:S0190-9622(22)03316.
     PubMed    
     
     
     
162. HAGHANI DOGAHE Z, Ghorbani A, Hallaj S, Mobayen M, et al
     Modified Score of Toxic Epidermal Necrolysis to predict toxic epidermal necrolysis mortality.
     J Am Acad Dermatol. 2023;88:254-255.
     PubMed    
     
     
     
163. MOSTOW E
     JAAD Game Changers *: A systematic review of the safety and efficacy of systemic corticosteroids in atopic dermatitis.
     J Am Acad Dermatol. 2023;88:269.
     PubMed    
     
     
     December 2022
164. LIMMER EE, Knowles A, Deng J, Parthasarathy V, et al
     Atopic Dermatitis is Associated with an Increased Risk of Keloids: A Case-Control Study.
     J Am Acad Dermatol. 2022 Dec 15:S0190-9622(22)03302.
     PubMed    
     
     
     
165. ABUABARA K, Eichenfield LF, Bissonnette R, Silverberg JI, et al
     Real-world evidence on atopic dermatitis: Baseline characteristics and predictors of treatment choice in the TARGET cohort.
     J Am Acad Dermatol. 2022 Dec 12:S0190-9622(22)02792.
     PubMed    
     
     
     
166. BECK LA, Bieber T, Weidinger S, Tauber M, et al
     Tralokinumab treatment improves the skin microbiota by increasing the microbial diversity in adults with moderate-to-severe atopic dermatitis: analysis of microbial diversity in ECZTRA 1, a randomized controlled trial.
     J Am Acad Dermatol. 2022 Dec 3:S0190-9622(22)03150.
     PubMed     Abstract available
     
     
     
167. SHTAYNBERGER B, Zippin JH
     The impact of cancer history on the prevalence of type IV hypersensitivity: A nine-year matched retrospective cohort study.
     J Am Acad Dermatol. 2022 Dec 1:S0190-9622(22)03151.
     PubMed    
     
     
     
168. QIAN MF, Li S, Honari G, Sarin KY, et al
     Sociodemographic disparities in patch testing for commercially insured patients with dermatitis: A retrospective analysis of administrative claims data.
     J Am Acad Dermatol. 2022;87:1411-1413.
     PubMed    
     
     
     
169. PARK SK, Kim JS, Seo HM
     Exposure to air pollution and incidence of atopic dermatitis in the general population: A national population-based retrospective cohort study.
     J Am Acad Dermatol. 2022;87:1321-1327.
     PubMed     Abstract available
     
     
     November 2022
170. PAPP K, Szepietowski JC, Kircik L, Toth D, et al
     Long-Term Safety and Disease Control With Ruxolitinib Cream in Atopic Dermatitis: Results From Two Phase 3 Studies.
     J Am Acad Dermatol. 2022 Nov 26:S0190-9622(22)03136.
     PubMed     Abstract available
     
     
     
171. XIONG M, Warshaw EM
     Popular Sunscreens Marketed to Individuals with Skin of Color: Cost, Marketing Claims, and Allergenic Ingredients.
     J Am Acad Dermatol. 2022 Nov 14. pii: S0190-9622(22)03006.
     PubMed     Abstract available
     
     
     
172. HEYMANN WR
     Eczema knowledge gaps: Patching things up.
     J Am Acad Dermatol. 2022;87:987-988.
     PubMed    
     
     
     
173. SILVERBERG JI, Patel N, Warshaw EM, DeKoven JG, et al
     Hand and foot dermatitis in patients referred for patch testing: Analysis of North American Contact Dermatitis Group Data, 2001-2018.
     J Am Acad Dermatol. 2022;87:1049-1059.
     PubMed     Abstract available
     
     
     
174. WARSHAW EM, Xiong M, Atwater AR, DeKoven JG, et al
     Patch testing with glucosides: The North American Contact Dermatitis Group experience, 2009-2018.
     J Am Acad Dermatol. 2022;87:1033-1041.
     PubMed     Abstract available
     
     
     
175. JIANG Q, Ruan JW, Niu MM, Fan GZ, et al
     A predictive system for Henoch-Schonlein purpura nephritis established by multivariate analysis plus nomogram model in Chinese hospitalized children: A retrospective cohort study.
     J Am Acad Dermatol. 2022;87:1137-1139.
     PubMed    
     
     
     
176. WARSHAW EM, Ruggiero JL, DeKoven JG, Pratt MD, et al
     Patch testing with ammonium persulfate: The North American Contact Dermatitis Group Experience, 2015-2018.
     J Am Acad Dermatol. 2022;87:1014-1023.
     PubMed     Abstract available
     
     
     
177. LISZEWSKI W, Zaidi AJ, Fournier E, Scheman A, et al
     Review of aluminum, paraben, and sulfate product disclaimers on personal care products.
     J Am Acad Dermatol. 2022;87:1081-1086.
     PubMed     Abstract available
     
     
     
178. NORRESLET LB, Edslev SM, Clausen ML, Flachs EM, et al
     Hand eczema and temporal variation of Staphylococcus aureus clonal complexes: A prospective observational study.
     J Am Acad Dermatol. 2022;87:1006-1013.
     PubMed     Abstract available
     
     
     
179. RUTHERFORD A, Glass DA 2nd, Savory S
     Dermatology in orbit: Anticipating skin care requirements in the space age.
     J Am Acad Dermatol. 2022;87:1223-1224.
     PubMed    
     
     
     October 2022
180. GORI N, Chiricozzi A, Peris K
     Response to Narla S et al.'s "Management of inadequate response and adverse effects to dupilumab in atopic dermatitis"."
     J Am Acad Dermatol. 2022 Oct 22. pii: S0190-9622(22)02967.
     PubMed    
     
     
     
181. VANLERBERGHE J, Dezoteux F, Martin C, Jachiet M, et al
     Effectiveness and tolerance of Janus kinase inhibitors for the treatment of recalcitrant atopic dermatitis in a real-life French multicenter adult cohort.
     J Am Acad Dermatol. 2022 Oct 21. pii: S0190-9622(22)02960.
     PubMed    
     
     
     
182. SMITH B, Collier MR, Devjani S, Han G, et al
     Association between atopic dermatitis and thyroid disease among United States adults in the 2001-2006 National Health and Nutrition Examination Survey.
     J Am Acad Dermatol. 2022 Oct 13. pii: S0190-9622(22)02888.
     PubMed    
     
     
     
183. SLOAN B
     This month in JAAD Case Reports: October 2022. Pseudochromhidrosis and Dupilumab.
     J Am Acad Dermatol. 2022;87:750.
     PubMed    
     
     
     September 2022
184. YANG AF, San Chun K, Yu L, Walter JR, et al
     Validation of a hand-mounted wearable sensor for scratching movements in adults with atopic dermatitis.
     J Am Acad Dermatol. 2022 Sep 22. pii: S0190-9622(22)02775.
     PubMed    
     
     
     
185. FAN R, Leasure AC, Damsky W, Cohen JM, et al
     Alcohol use disorder among adults with atopic dermatitis: A case-control study in the All of Us research program.
     J Am Acad Dermatol. 2022 Sep 21. pii: S0190-9622(22)02739.
     PubMed    
     
     
     
186. BLAUVELT A, Szepietowski JC, Papp K, Simpson EL, et al
     Itch-Free State in Patients With Atopic Dermatitis Treated With Ruxolitinib Cream: Pooled Analysis From Two Randomized Phase 3 Studies.
     J Am Acad Dermatol. 2022 Sep 13. pii: S0190-9622(22)02688.
     PubMed    
     
     
     
187. HADAVAND MA, Kaffenberger B, Cartron AM, Trinidad JCL, et al
     Clinical presentation and management of atypical and recalcitrant acute generalized exanthematous pustulosis.
     J Am Acad Dermatol. 2022;87:632-639.
     PubMed     Abstract available
     
     
     August 2022
188. JELOUSI S, Murase EM, Bai H, Botto NB, et al
     First, Do No Harm: The Urgent Need for Comprehensive Clinical Guidelines for Diagnostic Testing of Recalcitrant "Atopic Dermatitis".
     J Am Acad Dermatol. 2022 Aug 22. pii: S0190-9622(22)02404.
     PubMed    
     
     
     
189. KAMATH S
     JAAD Game Changers: Longitudinal atopic dermatitis control and persistence vary with timing of disease onset in children: A cohort study.
     J Am Acad Dermatol. 2022 Aug 3. pii: S0190-9622(22)02421.
     PubMed    
     
     
     
190. MAGYARI A, Ye M, Margolis DJ, McCulloch CE, et al
     Adult atopic eczema and the risk of dementia: A population-based cohort study.
     J Am Acad Dermatol. 2022;87:314-322.
     PubMed     Abstract available
     
     
     
191. ADELANWA A, Yousaf A, Fang W, Kolodney MS, et al
     Common filaggrin gene loss-of-function variants are associated with skin cancer risk.
     J Am Acad Dermatol. 2022;87:458-460.
     PubMed    
     
     
     
192. FOSCHI CM, Tam I, Schalock PC, Yu J, et al
     Patch testing results in skin of color: A retrospective review from the Massachusetts General Hospital contact dermatitis clinic.
     J Am Acad Dermatol. 2022;87:452-454.
     PubMed    
     
     
     
193. HAN JJ, Creadore A, Seminario-Vidal L, Micheletti R, et al
     Medical management of Stevens-Johnson syndrome/toxic epidermal necrolysis among North American dermatologists.
     J Am Acad Dermatol. 2022;87:429-431.
     PubMed    
     
     
     July 2022
194. GEIER J, Schubert S, Buhl T
     Glutaraldehyde sensitization does not explain reactivity to alkyl polyglucosides in personal care products: results from review of a large contact allergy database.
     J Am Acad Dermatol. 2022 Jul 20. pii: S0190-9622(22)02399.
     PubMed    
     
     
     
195. BLAUVELT A, Langley RG, Lacour JP, Toth D, et al
     Long-term 2-Year Safety and Efficacy of Tralokinumab in Adults with Moderate-to-severe Atopic Dermatitis: Interim Analysis of the ECZTEND Open-label Extension Trial.
     J Am Acad Dermatol. 2022 Jul 18. pii: S0190-9622(22)02345.
     PubMed     Abstract available
     
     
     
196. BRONIN A
     Emollients in infancy to prevent atopic dermatitis: A systematic review and meta-analysis.
     J Am Acad Dermatol. 2022 Jul 14. pii: S0190-9622(22)02263.
     PubMed    
     
     
     
197. O'CONNELL KA, Kim LS, Szeto MD, Sivesind T, et al
     From the Cochrane Library: Phototherapy for atopic eczema.
     J Am Acad Dermatol. 2022;87:e23-e26.
     PubMed    
     
     
     June 2022
198. SHETH AP, Blumstein AJ, Rangel S, Jackson KL, et al
     Three-Question Skindex-Mini Measures Quality of Life in Children with Atopic Dermatitis.
     J Am Acad Dermatol. 2022 Jun 23. pii: S0190-9622(22)02215.
     PubMed    
     
     
     
199. MENDES-BASTOS P, Ladizinski B, Guttman-Yassky E, Jiang P, et al
     Characterization of acne associated with upadacitinib treatment in patients with moderate-to-severe atopic dermatitis: a post hoc integrated analysis of three phase 3 randomized, double-blind, placebo-controlled trials.
     J Am Acad Dermatol. 2022 Jun 14. pii: S0190-9622(22)00996.
     PubMed     Abstract available
     
     
     
200. MOSCA M, Hadeler E, Hong J, Hakimi M, et al
     A cross-sectional study of ethnic and racial disparities in pediatric atopic dermatitis clinical trials.
     J Am Acad Dermatol. 2022 Jun 8. pii: S0190-9622(22)00908.
     PubMed    
     
     
     
201. AMORNRUK N, Siranart N, Sittiwattanawong P, Kueanjinda P, et al
     The immediate patch test reaction to fragrance in patients with allergic contact dermatitis to fragrance: A prospective study.
     J Am Acad Dermatol. 2022 Jun 8. pii: S0190-9622(22)00897.
     PubMed     Abstract available
     
     
     
202. AO S, Gao X, Zhan J, Ai L, et al
     Inhibition of tumor necrosis factor improves conventional steroid therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis in a cohort of patients.
     J Am Acad Dermatol. 2022;86:1236-1245.
     PubMed     Abstract available
     
     
     May 2022
203. CHATRATH S, Lei D, Yousaf M, Chavda R, et al
     Longitudinal course and predictors of depressive symptoms in atopic dermatitis.
     J Am Acad Dermatol. 2022 May 9. pii: S0190-9622(22)00792.
     PubMed     Abstract available
     
     
     
204. DE DR, Seivright J, Yee D, Hsiao JL, et al
     Readability, quality, and timeliness of patient online health resources for urticaria.
     J Am Acad Dermatol. 2022;86:1182-1185.
     PubMed    
     
     
     April 2022
205. SILVERBERG JI, Rangel SM, Sheth A, Blumstein A, et al
     Single-question parent-reported global atopic dermatitis severity: a valid instrument in children.
     J Am Acad Dermatol. 2022 Apr 27. pii: S0190-9622(22)00706.
     PubMed    
     
     
     
206. RICK JW, Morgan A, De DR, Hsiao JL, et al
     Allergens and Marketing Claims of The Most Popular Baby Moisturizers: A Product Analysis.
     J Am Acad Dermatol. 2022 Apr 26. pii: S0190-9622(22)00700.
     PubMed    
     
     
     
207. SHI VY, Bhutani T, Fonacier L, Deleuran M, et al
     Phase 3 Efficacy and Safety of Abrocitinib in Adults with Moderate-to-Severe Atopic Dermatitis After Switching from Dupilumab (JADE EXTEND).
     J Am Acad Dermatol. 2022 Apr 16. pii: S0190-9622(22)00608.
     PubMed     Abstract available
     
     
     
208. JELOUSI S, Butler DC
     Sleep Disturbances in Older Adults with Pruritic Eruptions: Implications Across Inconsistent Literature and a Commentary on "Association of Sleep Disturbances with Geriatric Age in Atopic Dermatitis Patients".
     J Am Acad Dermatol. 2022 Apr 11. pii: S0190-9622(22)00605.
     PubMed    
     
     
     
209. HEYMANN WR
     More than Mycoplasma-induced rash and mucositis: The potential role of Mycoplasma pneumoniae in Stevens-Johnson syndrome/toxic epidermal necrolysis.
     J Am Acad Dermatol. 2022;86:746-747.
     PubMed    
     
     
     
210. SILVERBERG JI, Hou A, Warshaw EM, DeKoven JG, et al
     Age-related differences in patch testing results among children: Analysis of North American Contact Dermatitis Group Data, 2001-2018.
     J Am Acad Dermatol. 2022;86:818-826.
     PubMed     Abstract available
     
     
     
211. LIEW YCC, Choo KJL, Oh CC, Pang SM, et al
     Mycoplasma-induced Stevens-Johnson syndrome/toxic epidermal necrolysis: Case-control analysis of a cohort managed in a specialized center.
     J Am Acad Dermatol. 2022;86:811-817.
     PubMed     Abstract available
     
     
     
212. DEKOVEN JG, DeKoven BM, Warshaw EM, Mathias CGT, et al
     Occupational contact dermatitis: Retrospective analysis of North American Contact Dermatitis Group Data, 2001 to 2016.
     J Am Acad Dermatol. 2022;86:782-790.
     PubMed     Abstract available
     
     
     
213. KOLITZ E, Karbhari N, Son T, Dominguez AR, et al
     Validation of two predictive models designed to aid clinicians in identifying Stevens-Johnson syndrome/toxic epidermal necrolysis: A single institution retrospective review.
     J Am Acad Dermatol. 2022;86:960-962.
     PubMed    
     
     
     
214. UGWU N, Cheraghlou S, Feng H, Cohen JM, et al
     Characterization of outpatient visits and treatments for urticaria in the United States adult population between 1998 and 2016.
     J Am Acad Dermatol. 2022;86:936-938.
     PubMed    
     
     
     March 2022
215. CHEN J, Cheng J, Yang H, Tu W, et al
     The Efficacy and Safety of Janus Kinase Inhibitors in Patients with Atopic Dermatitis: A Systematic Review and Meta-analysis.
     J Am Acad Dermatol. 2022 Mar 28. pii: S0190-9622(22)00529.
     PubMed    
     
     
     
216. FAN R, Leasure AC, Damsky W, Cohen JM, et al
     Association of Atopic Dermatitis with Attention Deficit Hyperactivity Disorder among US Adults in the All of Us Research Program: A Case-Control Study.
     J Am Acad Dermatol. 2022 Mar 10. pii: S0190-9622(22)00395.
     PubMed    
     
     
     
217. JU T, Labib A, Does AV, Yosipovitch G, et al
     Topical JAK-STAT inhibitor tofacitinib is effective in reducing non-atopic dermatitis chronic itch: a case series.
     J Am Acad Dermatol. 2022 Mar 9. pii: S0190-9622(22)00393.
     PubMed    
     
     
     
218. LIM JH, Lew BL, Sim WY, Kwon SH, et al
     Incidence of childhood-onset vitiligo and increased risk of atopic dermatitis, autoimmune diseases, and psoriasis: A nationwide population-based study.
     J Am Acad Dermatol. 2022 Mar 8. pii: S0190-9622(22)00390.
     PubMed    
     
     
     
219. KANTOR J
     This Month in JAAD International: May 2022: Atopic dermatitis severity and mental health.
     J Am Acad Dermatol. 2022 Mar 5. pii: S0190-9622(22)00368.
     PubMed    
     
     
     
220. SREEKANTASWAMY SA, Tully J, Edelman LS, Supiano MA, et al
     The Underrepresentation of Older Adults in Clinical Trials for JAK Inhibitors to Treat Atopic Dermatitis.
     J Am Acad Dermatol. 2022 Mar 1. pii: S0190-9622(22)00365.
     PubMed    
     
     
     
221. YANG CY, Chen SP, Wei JC
     Correspondence to "Association between psoriasis and asthma among United States adults in the 2009-2014 national health and nutrition examination survey".
     J Am Acad Dermatol. 2022;86:e117.
     PubMed    
     
     
     
222. MARTIN A, Thatiparthi A, Liu J, Ge S, et al
     Reply to "Correspondence to 'Association between psoriasis and asthma among United States adults in the 2009-2014 National Health and Nutrition Examination Survey'".
     J Am Acad Dermatol. 2022;86:e119-e120.
     PubMed    
     
     
     
223. MARTIN A, Thatiparthi A, Liu J, Ge S, et al
     Association between psoriasis and asthma among United States adults in the 2009-2014 National Health and Nutrition Examination Survey.
     J Am Acad Dermatol. 2022;86:709-712.
     PubMed    
     
     
     
224. WONGVIBULSIN S, Pahalyants V, Kalinich M, Murphy W, et al
     Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune-checkpoint inhibitors: A United States population-level analysis.
     J Am Acad Dermatol. 2022;86:563-572.
     PubMed     Abstract available
     
     
     
225. PATEL S, Cadwell JB, Lambert WC
     Effect of older age on complications and mortality in inpatients with Stevens-Johnson syndrome or toxic epidermal necrolysis.
     J Am Acad Dermatol. 2022;86:665-667.
     PubMed    
     
     
     February 2022
226. ZHENG DX, Cwalina TB, Jella TK, Cullison CR, et al
     Financial insecurity among U.S. children with atopic dermatitis.
     J Am Acad Dermatol. 2022 Feb 28. pii: S0190-9622(22)00362.
     PubMed    
     
     
     
227. DEL POZO DV, Zhu Y, Mitra N, Hoffstad OJ, et al
     The risk of atopic comorbidities and atopic march progression among Black and White children with mild to moderate atopic dermatitis: a cross-sectional study.
     J Am Acad Dermatol. 2022 Feb 19. pii: S0190-9622(22)00334.
     PubMed    
     
     
     
228. CHOVATIYA R, Silverberg JI
     Evaluating the Longitudinal Course of Atopic Dermatitis: a review of the literature.
     J Am Acad Dermatol. 2022 Feb 9. pii: S0190-9622(22)00253.
     PubMed    
     
     
     
229. THERIANOU A, Vincenzi C, Tosti A
     How safe is prescribing oral minoxidil in patients allergic to topical minoxidil?
     J Am Acad Dermatol. 2022;86:429-431.
     PubMed    
     
     
     January 2022
230. DAVIS DMR, Drucker AM, Alikhan A, Bercovitch L, et al
     AAD Guidelines: awareness of comorbidities associated with atopic dermatitis in adults.
     J Am Acad Dermatol. 2022 Jan 24. pii: S0190-9622(22)00080.
     PubMed     Abstract available
     
     
     
231. PALLER AS, Guttman-Yassky E, Schuttelaar MLA, Irvine AD, et al
     Disease Characteristics, Comorbidities, Treatment Patterns and Quality of Life Impact in Children <12 Years Old with Atopic Dermatitis: Interim Results from the PEDISTAD Real-World Registry.
     J Am Acad Dermatol. 2022 Jan 23. pii: S0190-9622(22)00092.
     PubMed    
     
     
     December 2021
232. GAU SY
     Antibiotic Exposures Could Lead to Overestimation of Incident Outcomes-a Commentary on "Prevalence of type 2 inflammatory diseases in pediatric patients with atopic dermatitis: real-world evidence."
     J Am Acad Dermatol. 2021 Dec 20. pii: S0190-9622(21)02992.
     PubMed    
     
     
     
233. DAL BELLO G, Maurelli M, Schena D, Gisondi P, et al
     Variations of symptoms of atopic dermatitis and psoriasis in relation to menstrual cycle.
     J Am Acad Dermatol. 2021 Dec 14. pii: S0190-9622(21)02975.
     PubMed    
     
     
     
234. ATWATER AR, Bembry R, Liu B, Warshaw EM, et al
     Medical Adhesive Allergens: Retrospective Analysis of Cross-Sectional Data from the North American Contact Dermatitis Group, 2001-2018.
     J Am Acad Dermatol. 2021 Dec 4. pii: S0190-9622(21)02927.
     PubMed     Abstract available
     
     
     
235. COIFFARD LJM, Couteau C
     Are alkyl glucosides really allergens?
     J Am Acad Dermatol. 2021;85:e355.
     PubMed    
     
     
     
236. MUFTI A, Sachdeva M, Kim P, Rahat S, et al
     A systematic review of eczematous eruptions in patients receiving biologic therapy.
     J Am Acad Dermatol. 2021;85:1630-1635.
     PubMed    
     
     
     
237. RINOLDI PO, Bronz G, Ferrarini A, Mangas C, et al
     Acute hemorrhagic edema: Uncommon features.
     J Am Acad Dermatol. 2021;85:1620-1621.
     PubMed    
     
     
     
238. AL MUSALHI BH, Al Kamzari A, Al Kindi F, Al Abrawi S, et al
     Clinical spectrum of childhood-onset hypocomplementemic urticarial vasculitis in Oman: A retrospective multicenter study.
     J Am Acad Dermatol. 2021;85:1617-1620.
     PubMed    
     
     
     
239. HIROTSU KE, Rana J, Wang JY, Raghavan SS, et al
     Clinicopathologic characterization of enfortumab vedotin-associated cutaneous toxicity in patients with urothelial carcinoma.
     J Am Acad Dermatol. 2021;85:1610-1611.
     PubMed    
     
     
     
240. MCCORMACK L, Thompson LL, Chang MS, Polyakov N, et al
     Cutaneous adverse events to immune checkpoint inhibitors in pediatric populations: A retrospective cohort study.
     J Am Acad Dermatol. 2021;85:1587-1589.
     PubMed    
     
     
     
241. BETTUZZI T, Ingen-Housz-Oro S, Purtillo CC, Le Cleach L, et al
     Changing spectrum of suspected drugs of epidermal necrolysis: A World Health Organization pharmacovigilance database analysis from 1997-2020.
     J Am Acad Dermatol. 2021;85:1581-1584.
     PubMed    
     
     
     
242. WARSHAW EM, Schlarbaum JP, Silverberg JI, DeKoven JG, et al
     Contact dermatitis to personal care products is increasing (but different!) in males and females: North American Contact Dermatitis Group data, 1996-2016.
     J Am Acad Dermatol. 2021;85:1446-1455.
     PubMed     Abstract available
     
     
     
243. CHOVATIYA R, Silverberg JI
     Association of herpes zoster and chronic inflammatory skin disease in US inpatients.
     J Am Acad Dermatol. 2021;85:1437-1445.
     PubMed     Abstract available
     
     
     November 2021
244. GUO L, Bai H, Botto N, Woodruff CM, et al
     Allergens and Marketing Claims in Commercial Hand Sanitizers: A Cross-Sectional Study.
     J Am Acad Dermatol. 2021 Nov 24. pii: S0190-9622(21)02895.
     PubMed    
     
     
     
245. ROH YS, Huang AH, Sutaria N, Choi U, et al
     Real-world comorbidities of atopic dermatitis in the U.S. adult ambulatory population.
     J Am Acad Dermatol. 2021 Nov 17. pii: S0190-9622(21)02838.
     PubMed     Abstract available
     
     
     
246. CHOVATIYA R, Silverberg JI
     DESCRIBE-AD: A Novel Classification Framework for Atopic Dermatitis.
     J Am Acad Dermatol. 2021 Nov 10. pii: S0190-9622(21)02795.
     PubMed     Abstract available
     
     
     
247. KAMEL K, Militello M, Sivesind TE, Szeto MD, et al
     From the Cochrane Library: Psychologic and educational interventions for atopic eczema in children.
     J Am Acad Dermatol. 2021;85:e309-e311.
     PubMed    
     
     
     
248. CHENG HM, Tey HL
     Response to: Momen et al's "Discriminating minor and major forms of drug reaction with eosinophilia and systemic symptoms: Facial edema aligns to the severe phenotype".
     J Am Acad Dermatol. 2021;85:e303-e304.
     PubMed    
     
     
     
249. CHERAGHLOU S, Watsky KL, Cohen JM
     Utilization, cost, and provider trends in patch testing among Medicare beneficiaries in the United States from 2012 to 2017.
     J Am Acad Dermatol. 2021;85:1218-1226.
     PubMed     Abstract available
     
     
     October 2021
250. PALLER AS, Mina-Osorio P, Vekeman F, Boklage S, et al
     Prevalence of type 2 inflammatory diseases in pediatric patients with atopic dermatitis: real-world evidence.
     J Am Acad Dermatol. 2021 Oct 28. pii: S0190-9622(21)02720.
     PubMed     Abstract available
     
     
     
251. SAEKI H, Ito K, Yokota D, Tsubouchi H, et al
     Difamilast ointment in adult patients with atopic dermatitis: A phase 3 randomized double-blind vehicle-controlled trial.
     J Am Acad Dermatol. 2021 Oct 25. pii: S0190-9622(21)02682.
     PubMed     Abstract available
     
     
     
252. GHAFARI G, Liszewski W
     Comparison of the formulation and allergenic potential of "clean" and traditional shampoos.
     J Am Acad Dermatol. 2021 Oct 22. pii: S0190-9622(21)02684.
     PubMed    
     
     
     
253. KAUPPI S, Jokelainen J, Timonen M, Tasanen K, et al
     Atopic dermatitis and the risk of eating disorders: a population-based cohort study.
     J Am Acad Dermatol. 2021 Oct 21. pii: S0190-9622(21)02674.
     PubMed    
     
     
     
254. RAKITA U, Kaundinya T, Silverberg JI
     Lack of association between atopic dermatitis severity and worsening during pregnancy: a cross-sectional study.
     J Am Acad Dermatol. 2021 Oct 7. pii: S0190-9622(21)02585.
     PubMed    
     
     
     
255. WU JJ, Martin A, Liu J, Thatiparthi A, et al
     The risk of COVID-19 infection in patients with atopic dermatitis - a retrospective cohort study.
     J Am Acad Dermatol. 2021 Oct 6. pii: S0190-9622(21)02578.
     PubMed    
     
     
     
256. QUACH HT, Johnson DB, LeBoeuf NR, Zwerner JP, et al
     Cutaneous adverse events caused by immune checkpoint inhibitors.
     J Am Acad Dermatol. 2021;85:956-966.
     PubMed     Abstract available
     
     
     
257. DUPLISEA MJ, Roberson ML, Chrisco L, Strassle PD, et al
     Performance of ABCD-10 and SCORTEN mortality prediction models in a cohort of patients with Stevens-Johnson syndrome/toxic epidermal necrolysis.
     J Am Acad Dermatol. 2021;85:873-877.
     PubMed     Abstract available
     
     
     
258. CHOUDHARY R, Vinay K, Srivastava N, Bishnoi A, et al
     Clinical, biochemical, and serologic predictors of drug reaction with eosinophilia and systemic symptoms syndrome: A prospective case-control study.
     J Am Acad Dermatol. 2021;85:901-909.
     PubMed     Abstract available
     
     
     
259. SACHDEVA M, Mufti A, Kim P, Maliyar K, et al
     Biologic treatment in pediatric Stevens-Johnson syndrome/toxic epidermal necrolysis: A systematic review.
     J Am Acad Dermatol. 2021;85:1011-1013.
     PubMed    
     
     
     September 2021
260. SILVERBERG JI, Hou A, Warshaw EM, Maibach HI, et al
     Prevalence and Trend of Allergen Sensitization in Patients with a Diagnosis of Seborrheic Dermatitis After Patch Testing, North American Contact Dermatitis Group Data, 2001-2016.
     J Am Acad Dermatol. 2021 Sep 25. pii: S0190-9622(21)02522.
     PubMed    
     
     
     
261. MOLOGOUSIS M, Goldminz AM
     References for Common Contact Allergens Present in Prescription Topical Corticosteroids.
     J Am Acad Dermatol. 2021 Sep 24. pii: S0190-9622(21)02490.
     PubMed    
     
     
     
262. HUGHES ME, Aralis H, Bruhn KW, Cotliar J, et al
     A reliability study using Network-Oriented Research Assistant to evaluate the use of digital photographs in the assessment of atopic dermatitis.
     J Am Acad Dermatol. 2021;85:725-726.
     PubMed    
     
     
     
263. WALDMAN RA, DeWane ME, Sloan SB, King B, et al
     Dupilumab ocular surface disease occurs predominantly in patients receiving dupilumab for atopic dermatitis: A multi-institution retrospective chart review.
     J Am Acad Dermatol. 2021;85:735-736.
     PubMed    
     
     
     
264. MOMEN SE, Diaz-Cano S, Walsh S, Creamer D, et al
     Discriminating minor and major forms of drug reaction with eosinophilia and systemic symptoms: Facial edema aligns to the severe phenotype.
     J Am Acad Dermatol. 2021;85:645-652.
     PubMed     Abstract available
     
     
     September 2020
265. LYTVYN Y, Mufti A, Sachdeva M, Maliyar K, et al
     Stevens Johnson Syndrome and Toxic Epidermal Necrolysis Reactions to BRAF and MEK Inhibitors in Patients with Melanoma: A Systematic Review.
     J Am Acad Dermatol. 2020 Sep 11. pii: S0190-9622(20)32613.
     PubMed    
     
     

Thank you for your interest in scientific medicine.

AMEDEO Hypersensitivity Reaction is free of charge.